公开(公告)号：US08663683B2

公开(公告)日：2014-03-04

申请号：US13595103

申请日：2012-08-27

申请人： Likan Liang ,  Hua Wang ,  Padmanabh P. Bhatt ,  Michael L. Vieira

发明人： Likan Liang ,  Hua Wang ,  Padmanabh P. Bhatt ,  Michael L. Vieira

IPC分类号： A61K31/35 ,  A61K9/24 ,  A61K9/54 ,  A61P3/10 ,  A61P25/02 ,  A61P25/06

CPC分类号： A61K9/5042 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/209 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/357 ,  A61K31/7048 ,  A61K45/06 ,  A61K47/48969 ,  A61K47/6951 ,  B82Y5/00 ,  Y02A50/465

摘要： Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

公开(公告)号：US08598191B2

公开(公告)日：2013-12-03

申请号：US13476369

申请日：2012-05-21

申请人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

发明人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K9/28

CPC分类号： A61K9/5031 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/19

摘要： The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

摘要翻译： 本发明涉及含有γ-羟基丁酸的即时释放组分和γ-羟基丁酸的一种或多种延迟/控制释放组分的口服脉冲释放药物剂型。

公开(公告)号：US20120231085A1

公开(公告)日：2012-09-13

申请号：US13476369

申请日：2012-05-21

申请人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

发明人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

IPC分类号： A61K31/19 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  A61P25/16 ,  A61P9/12 ,  A61P9/10 ,  A61P7/00 ,  A61P35/00 ,  A61P23/00 ,  A61P5/06 ,  A61P15/00 ,  A61P3/04 ,  A61P21/02 ,  A61P21/06 ,  A61K9/14

CPC分类号： A61K9/5031 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/19

摘要： The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

摘要翻译： 本发明涉及含有γ-羟基丁酸的即时释放组分和γ-羟基丁酸的一种或多种延迟/控制释放组分的口服脉冲释放药物剂型。

公开(公告)号：US08193211B2

公开(公告)日：2012-06-05

申请号：US11239638

申请日：2005-09-30

申请人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

发明人： Likan Liang ,  Niraj Shah ,  Padmanabh P. Bhatt ,  Scott Ibrahim

IPC分类号： A61K31/44 ,  A61K47/00

CPC分类号： A61K9/5031 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/19

摘要： The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

摘要翻译： 本发明涉及含有γ-羟基丁酸的即时释放组分和γ-羟基丁酸的一种或多种延迟/控制释放组分的口服脉冲释放药物剂型。

公开(公告)号：US20110287099A1

公开(公告)日：2011-11-24

申请号：US12926931

申请日：2010-12-17

申请人： Likan Liang ,  Hua Wang ,  Padmanabh P. Bhatt ,  Michael L. Vieira

发明人： Likan Liang ,  Hua Wang ,  Padmanabh P. Bhatt ,  Michael L. Vieira

IPC分类号： A61K9/22 ,  A61K9/14 ,  A61P25/00 ,  A61K31/357

CPC分类号： A61K9/5042 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/209 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/357 ,  A61K31/7048 ,  A61K45/06 ,  A61K47/48969 ,  A61K47/6951 ,  B82Y5/00 ,  Y02A50/465

摘要： Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

摘要翻译： 提供了托吡酯每日一次口服给药的药物组合物。 制剂包含缓释组分和任选的快速释放组分，其组合物可分别选择性地调节以沿预定释放曲线释放活性成分。 还提供了治疗或预防哺乳动物受试者中包括施用本文公开的新型制剂的病理学障碍的方法。

公开(公告)号：US20110251198A1

公开(公告)日：2011-10-13

申请号：US13084612

申请日：2011-04-12

申请人： Likan Liang ,  Padmanabh P. Bhatt ,  David Dain ,  Jean-Philippe Taquet ,  Aleksandr Pechenov ,  Alexei Tchesnokov ,  Reynold Mariaux

发明人： Likan Liang ,  Padmanabh P. Bhatt ,  David Dain ,  Jean-Philippe Taquet ,  Aleksandr Pechenov ,  Alexei Tchesnokov ,  Reynold Mariaux

IPC分类号： A61K31/535 ,  C07C215/20 ,  A61P25/00 ,  A61P25/24 ,  A61P25/32 ,  C07D265/30 ,  C07D265/32

CPC分类号： C07D265/30 ,  C07C215/08 ,  C07C217/34 ,  C07D265/32

摘要： Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

摘要翻译： 本文提供了维罗他嗪及其各种盐的制备方法，以及与维甲内酯相关的化合物，例如新的中间体反应产物及其多晶型物。 特别地，该方法提供基本上纯的维罗他嗪HCl的API，同时避免不期望的杂质。 该方法进一步提供了分离，鉴定和表征viloxazine的新型多晶型物。 还提供了用于合成和鉴定和描述维罗他嗪的新型中间体的方法，以及一些重要的代谢产物和维罗他嗪代谢物的前体。

公开(公告)号：US06511677B1

公开(公告)日：2003-01-28

申请号：US09714103

申请日：2000-11-17

申请人： Robert N Brey ,  Likan Liang

发明人： Robert N Brey ,  Likan Liang

IPC分类号： A61K9127

CPC分类号： C07C69/587 ,  A61K9/1271 ,  A61K9/1273 ,  C11C3/00

摘要： The invention relates to an oral drug delivery system which delivers biologically active substances to the mucosal tissue of the intestine utilizing novel polymerized liposomes. Novel polymerizable fatty acids having a polymerizable group, a surfactant group, and a functional group, and optionally coupled to ligands which target mucosal tissue in the intestine are disclosed. Novel negatively charged polymerizable lipids which have phosphatidyl inositol (PI), phosphatidyl glycerol (PG) or phosphatidyl serine (PS) groups on a polymerizable backbone are also described.

公开(公告)号：US06500453B2

公开(公告)日：2002-12-31

申请号：US10013689

申请日：2001-12-13

申请人： Robert N Brey ,  Likan Liang

发明人： Robert N Brey ,  Likan Liang

IPC分类号： A61K9127

CPC分类号： C07C69/587 ,  A61K9/1271 ,  A61K9/1273 ,  C11C3/00

摘要： The invention relates to an oral drug delivery system which delivers biologically active substances to the mucosal tissue of the intestine utilizing novel polymerized liposomes. Novel polymerizable fatty acids having a polymerizable group, a surfactant group, and a functional group, and optionally coupled to ligands which target mucosal tissue in the intestine are disclosed. Novel negatively charged polymerizable lipids which have phosphatidyl inositol (PI), phosphatidyl glycerol (PG) or phosphatidyl serine (PS) groups on a polymerizable backbone are also described.

摘要翻译： 本发明涉及使用新型聚合脂质体将生物活性物质输送到肠粘膜组织的口服药物递送系统。 公开了具有可聚合基团，表面活性剂组和官能团的新型可聚合脂肪酸，并且任选地与靶向肠内粘膜组织的配体偶联。 还描述了在可聚合主链上具有磷脂酰肌醇（PI），磷脂酰甘油（PG）或磷脂酰丝氨酸（PS）基团的新型带负电荷的可聚合脂质。